IP Library Granted Patent US 11,802,270
Granted Patent B2
US 11,802,270 · App. 15/501,607 · Granted Oct 31, 2023

Microphysiologic methods and compositions

Inventors: Alessandra Balduini (Pavia, IT); David L. Kaplan (Concord, MA); Lindsay Wray (Fairfield, CA); Christian Andrea Di Buduo (Pavia, IT); Lorenzo Tozzi (Pavia, IT)
Assignees: Tufts University; University of Pavia
C12N5/0644C12N2502/28C12N2533/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,802,270
App. No.
15/501,607
Granted
Oct 31, 2023
Kind
B2
Abstract

The present invention provides, among other things, methods for producing platelets including the steps of providing a silk membrane about 2 μm and 100 μm thick, inclusive, contacting the silk membrane with a porogen to form a porous silk membrane comprising at least one silk wall defining a lumen, associating the porous silk membrane with stromal derived factor-1? and at least one functionalizing agent, forming a three dimensional silk matrix comprising interconnected pores wherein the pores have a diameter of between about 5 and 500 μm, inclusive, wherein the silk matrix is formed around at least a portion of the porous silk membrane, introducing a plurality of megakaryocytes to the silk matrix such that the megakaryocytes are located at least partially within the porous silk matrix, and stimulating the plurality of megakaryocytes to produce platelets. Also provided are various new compositions and methods of making those compositions.

Claims (41)

1. A composition comprising:

a porous silk membrane between about 2 μm and 100 μm thick, inclusive, comprising at least one silk wall defining a lumen;

at least one functionalizing agent selected from the group consisting of fibronectin, collagen type IV, collagen type VI, von Willebrand factor, laminin, and fibrinogen;

stromal derived factor-1α; and

a three dimensional silk matrix comprising pores, wherein the pores are interconnected and the pores have a diameter of between about 5 and 500 μm, inclusive,

wherein the three dimensional silk matrix at least partially surrounds the porous silk membrane, and

wherein the stromal derived factor-1α is associated with the porous silk membrane,

wherein the composition is adapted to receive a plurality of megakaryocytes that, in use, produce differentiated and functional platelets.

2. The composition of claim 1 , further comprising a plurality of endothelial cells located at least partially within the lumen.

3. The composition of claim 2 , wherein the plurality of endothelial cells are selected from the group consisting of human dermal microvascular endothelial cells, human umbilical vein endothelial cells, and primary human endothelial cells.

4. The composition of claim 2 , wherein the plurality of endothelial cells form a confluent layer.

5. The composition of claim 4 , wherein the confluent layer of the plurality of endothelial cells exhibit a cobblestone morphology and/or VE-cadherin staining.

6. The composition of claim 1 , further comprising the plurality of megakaryocytes located at least partially within the three dimensional silk matrix.

7. The composition of claim 6 , further comprising culture media flowing through the composition at a flow rate of about 20 μL/minute to 250 μL/minute.

8. The composition of claim 6 , wherein the plurality of megakaryocytes produce platelets in the lumen.

9. The composition of claim 8 , wherein at least 70% of the platelets produced from the plurality of megakaryocytes express CD61.

10. The composition of claim 8 , wherein the platelets produced from the plurality of megakaryocytes exhibit a similar morphology and CD41 positive staining as compared to platelets isolated from peripheral blood.

11. The composition of claim 8 , wherein about 30 to 3000 fold more platelets are produced per seeded cell when in the presence of endothelial cells as compared to a seeded cell not in the presence of endothelial cells.

12. The composition of claim 8 , wherein the composition is characterized as being able to produce about 0.8×10 6 to about 2.0×10 6 platelets in about 6 hours.

13. The composition of claim 8 , wherein the platelets produced from the plurality of megakaryocytes bind PAC-1.

14. The composition of claim 13 , wherein the platelets produced from the plurality of megakaryocytes bind PAC-1 following stimulation with thrombin, ADP and/or epinephrine.

15. The composition of claim 1 , wherein the porous silk membrane is tubular.

16. The composition of claim 1 , wherein the pores in the silk membrane have a diameter between about 1-50 μm, inclusive.

17. The composition of claim 1 , wherein the porous silk membrane is about 50-70 μm thick, inclusive.

18. The composition of claim 1 , wherein the pores of the three dimensional silk matrix have a diameter of between about 300 and 500 μm, inclusive.

19. The composition of claim 1 , wherein the porous silk membrane is made via gel spinning.

20. The composition of claim 1 , wherein the plurality of megakaryocytes comprises at least 2.0×10 5 megakaryocytes.

21. A method of forming the composition of claim 1 comprising:

providing a silk membrane between about 2 μm and 100 μm thick, inclusive;

contacting the silk membrane with a porogen to form a porous silk membrane comprising at least one silk wall defining a lumen;

associating the porous silk membrane with stromal derived factor-1α and at least one functionalizing agent selected from the group consisting of fibronectin, collagen type IV, collagen type VI, von Willebrand factor, laminin, and fibrinogen; and

forming a three dimensional silk matrix comprising pores, wherein the pores are interconnected and the pores have a diameter of between about 5 and 500 μm, inclusive, and

wherein the three dimensional silk matrix is formed around at least a portion of the porous silk membrane, thereby forming a composition adapted to receive a plurality of megakaryocytes that, in use, produce differentiated and functional platelets.

22. A method of producing platelets, the method comprising:

providing a silk membrane between about 2 μm and 100 μm thick, inclusive;

contacting the silk membrane with a porogen to form a porous silk membrane comprising at least one silk wall defining a lumen;

associating the porous silk membrane with stromal derived factor-1α and at least one functionalizing agent selected from the group consisting of fibronectin, collagen type IV, collagen type VI, von Willebrand factor, laminin, and fibrinogen;

forming a three dimensional silk matrix comprising pores, wherein the pores are interconnected and the pores have a diameter of between about 5 and 500 μm, inclusive, wherein the three dimensional silk matrix is formed around at least a portion of the porous silk membrane;

introducing a plurality of megakaryocytes to the three dimensional silk matrix such that the plurality of megakaryocytes are located at least partially within the porous silk membrane; and

stimulating the plurality of megakaryocytes to produce differentiated and functional platelets.

23. A method of producing platelets, the method comprising activating a system comprising the composition of claim 1 , the composition also comprising megakaryocytes, wherein at least about 0.8×10 6 to about 2.0×10 6 platelets are produced by the system in 6 hours.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE INVENTOR NAME FROM DIBUDUO TO DI BUDUO PREVIOUSLY RECORDED AT REEL: 047563 FRAME: 0663. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 10, 2023
From: DI BUDUO, CHRISTIAN ANDREA
To: UNIVERSITY OF PAVIA
Reel/Frame 064238/0911 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INVENTOR NAME FROM LOPENZO TO LORENZO PREVIOUSLY RECORDED ON REEL 047563 FRAME 0554. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 10, 2023
From: BALDUNI, ALESSANDRA; KAPLAN, DAVID L.; WRAY, LINDSAY; TOZZI, LORENZO; CHEN, YING
To: TUFTS UNIVERSITY
Reel/Frame 064239/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2018
From: BALDUNI, ALESSANDRA; KAPLAN, DAVID L; WRAY, LINDSAY; TOZZI, LOPENZO; CHEN, YING
To: TUFTS UNIVERSITY
Reel/Frame 047563/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2018
From: DIBUDUO, CHRISTIAN ANDREA
To: UNIVERSITY OF PAVIA
Reel/Frame 047563/0663 →
CONFIRMATORY LICENSE Recorded Jun 7, 2018
From: TUFTS UNIVERSITY BOSTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046317/0280 →
Continuity (2)
Provisional Application 62034727 · Aug 7, 2014
Related Publication 20170218339A1 · Aug 3, 2017